Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling

Targeting the interleukin-6 (IL-6)/glycoprotein 130 (GP130) signaling pathway holds significant promise for cancer therapy given its essential role in the survival and progression of various cancer types. We have identified that bazedoxifene (BZA), a Food and Drug Administration (FDA)-approved drug...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology (Toronto) 2024-09, Vol.31 (10), p.5737-5751
Main Authors: Shi, Changyou, Bopp, Taylor, Lo, Hui-Wen, Tkaczuk, Katherine, Lin, Jiayuh
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Bazedoxifene
Benzoic acid
Cancer
cancer therapy
Chemotherapy
Conjugated estrogens
Cytokine Receptor gp130 - metabolism
Development and progression
Drug approval
Fulvestrant
GP130
Health aspects
Humans
IL-6
Indoles - pharmacology
Indoles - therapeutic use
Interleukin-6 - metabolism
Interleukins
Neoplasms - drug therapy
Oncology, Experimental
Osteoporosis
Patient compliance
Pertuzumab
Postmenopausal women
Prevention
Review
Signal Transduction - drug effects
STAT3
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeting the interleukin-6 (IL-6)/glycoprotein 130 (GP130) signaling pathway holds significant promise for cancer therapy given its essential role in the survival and progression of various cancer types. We have identified that bazedoxifene (BZA), a Food and Drug Administration (FDA)-approved drug used for the prevention of postmenopausal osteoporosis, when combined with conjugated estrogens in Duavee, also has a novel function as an inhibitor of IL-6/GP130 interaction. BZA is currently under investigation for its potential anticancer therapeutic function through the inhibition of the IL-6/GP130 pathway. Numerous studies have highlighted the efficacy of BZA (monotherapy or combined with other chemotherapy drugs) in impeding progression across multiple cancers. In this review, we mainly focus on the anticancer activity of BZA and the underlying anticancer mechanism through inhibition of the IL-6/GP130 pathway, aiming to provide valuable insights for the design and execution of further research and the potential repositioning of BZA in oncological clinical trials.
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3390/curroncol31100426